Journal
TRENDS IN CELL BIOLOGY
Volume 29, Issue 1, Pages 31-43Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tcb.2018.07.006
Keywords
-
Categories
Funding
- Canadian Institutes of Health Research (CIHR) [201512MSH-360794-228629]
- Princess Margaret Cancer Foundation
- Canada Research Chair [950-231346]
- CIHR Foundation Grant [FDN 148430]
- NSERC [489073]
- Canadian Cancer Society [703716]
- Ontario Institute for Cancer Research (OICR)
- province of Ontario
- Vanier Canada Graduate Scholarship (Vanier CGS) by CIHR
Ask authors/readers for more resources
During cancer initiation and progression, the somatic epigenome is broadly reprogrammed. This reprogramming can be a consequence of several processes, including altered transcriptional profiles and mutations. In addition, immune cells infiltrating the tumor microenvironment display a reprogrammed epigenome. For instance, tumor infiltrating T cells frequently exhibit an exhausted phenotype characterized by aberrant DNA methylation. Moreover, these aberrant epigenomes of cancer cells and infiltrating immune cells may represent a cancer vulnerability. Accumulating evidence supports the potential of using epigenetic therapy to not only reactivate silenced genes in cancer cells, but to also increase antitumor immunogenicity, by reactivation of endogenous retroviruses, to increase tumor immune-infiltration, and to reinvigorate T cell exhaustion. These findings highlight the potential synergies between epigenetic therapies and immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available